bermekimab

mAbexperimental

Bermekimab is a human monoclonal antibody of IgG1k isotype targeting Interleukin 1 alpha (IL1A). As of March 2017, bermekimab is in phase III clinical trials as an immunotherapy for colorectal cancer and as of September 2018 in phase II clinical trials for the treatment of atopic dermatitis. — Wikipedia

Clinical trial activity

11 trials · 4 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started May 21, 2018 (NCT03496974)

Timeline

2010s

Jan 1, 2018
Earliest Phase 2 Sponsor(trial)

2020s

Jan 1, 2020
Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

Interleukin-1 alphaINHIBITOR
IL1A inhibitor
- Interleukin-1 alpha (IL1A) ↗

Chemistry & pharmacology

Multi-specific: No

Oral

Parenteral

Topical

Sources

WikipediaBermekimab ↗

Also known as

human igg1 monoclonal antibody specific for human interleukin-1 alpha

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT05252520	Phase 1	May 1, 2023	—
NCT04988308	Phase 2	Oct 12, 2021	Janssen Pharmaceutica NV
NCT04990440	Phase 2	Sep 2, 2021	Janssen Pharmaceutica NV
NCT04791319	Phase 2	May 3, 2021	Janssen Pharmaceutica NV
NCT04544826	Phase 1	Oct 16, 2020	Janssen Pharmaceutica NV
NCT04544813	Phase 1	Oct 13, 2020	Janssen Pharmaceutica NV
NCT04021862	Phase 2	Nov 30, 2019	XBiotech, Inc.
NCT04019041	Phase 2	Sep 30, 2019	Icahn School of Medicine at Mount Sinai, XBiotech, Inc.
NCT04045743	Phase 2	Jul 19, 2019	Hellenic Institute for the Study of Sepsis
NCT03512275	Phase 2	Jun 20, 2018	XBiotech, Inc.
NCT03496974	Phase 2	May 21, 2018	XBiotech, Inc.

Showing 11 of 11 trials

Page 1 / 1

Organizations

Research & Development (4)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Janssen Pharmaceutica NV	For profit	5	5	2	2020
XBiotech, Inc.	For profit	4	4	1	2018
Hellenic Institute for the Study of Sepsis	Academic/Hospital	1	1	1	2019
Icahn School of Medicine at Mount Sinai	Academic/Hospital	1	0	1	2019

4 organizations

Page 1 / 1